Last reviewed · How we verify
Metoclopramide Sulfone
Metoclopramide Sulfone, marketed by King Chulalongkorn Memorial Hospital, is a drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a unique mechanism of action that differentiates it from competitors. The primary risk is the potential for increased competition post-patent expiry in 2028.
At a glance
| Generic name | Metoclopramide Sulfone |
|---|---|
| Sponsor | King Chulalongkorn Memorial Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metoclopramide for Gastric Visualization in Active Upper GI Bleeding (PHASE4)
- Metoclopramide vs Placebo for Prevention of Pneumonia in Acute Stroke (PHASE4)
- Migraine Treatment in ED (NA)
- Drug and Non-Drug Treatment Of Severe Migraine (PHASE4)
- Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metoclopramide Sulfone CI brief — competitive landscape report
- Metoclopramide Sulfone updates RSS · CI watch RSS
- King Chulalongkorn Memorial Hospital portfolio CI